Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple statements are inconsistent with the provided label excerpts, including contraindications (none listed), hepatotoxicity severity thresholds, and several safety/monitoring quantifications that are not supported by the supplied text. Some drug-interaction concepts align (CYP3A inhibitors and avoidance), but overall alignment is poor.
Category Scores
Accurate Statements
Lurbinectedin requires dose adjustments or avoidance in patients with moderate to severe liver dysfunction.
2.4 Dosage Modifications for Patients with Severe and Moderate Hepatic Impairment: Avoid in severe hepatic impairment (total bilirubin > 3×ULN); in moderate hepatic impairment (total bilirubin >1.5 to ≤3×ULN) recommended dosage 1.6 mg/m2 every 21 days.
Combining lurbinectedin with strong CYP3A inhibitors (e.g., ketoconazole) raises lurbinectedin exposure.
7.1 Effect of Other Drugs on ZEPZELCA: Coadministration with strong CYP3A inhibitor increases systemic exposure; example given: itraconazole AUC 2.7-fold.
Strong CYP3A inhibitors increase lurbinectedin toxicity, and use should be avoided or the dose reduced.
7.1: Avoid coadministration with strong or moderate CYP3A inhibitors; if cannot be avoided, reduce dose. Also: increased incidence and severity of adverse reactions may occur.
Monitor blood counts including neutrophils, red blood cells and platelets prior to each ZEPZELCA administration.
5.1 Myelosuppression: 'Monitor blood counts including neutrophils, red blood cells and platelets prior to each ZEPZELCA administration.'
Caution is required in end-stage renal disease due to limited data for lurbinectedin.
12.3 Pharmacokinetics: 'The effects of severe renal impairment (CLcr < 30 mL/min) ... have not been studied.'
Unsupported Statements
Common side effects of lurbinectedin include fatigue, nausea, decreased appetite, pneumonia, and myelosuppression.
The provided label excerpts (sections shown) do not list a side-effect profile including these items.
No unique side effects target specific racial or ethnic groups.
No race/ethnicity-specific safety statement is present in the provided excerpts.
Older adults (over 65) report higher rates of serious adverse events during lurbinectedin clinical trials, including cytopenias and infections.
8.5 provides differences in serious adverse reactions for ≥65 in the IMforte and SCLC settings, but it does not specifically state 'infections' as a category, nor the exact 'over 65 report higher rates' phrasing with cytopenias/infections together in the provided excerpt.
Lurbinectedin use in the setting of bilirubin above the upper limit of normal or AST/ALT more than three times the upper limit increases toxicity risks like hepatotoxicity.
5.2 and 2.4 discuss hepatotoxicity generally and dosing modifications by bilirubin thresholds; the excerpt does not explicitly state 'increases toxicity risks like hepatotoxicity' for the specific 'bilirubin > ULN' or 'AST/ALT >3×ULN' criteria as an actionable statement.
No specific dose adjustments are recommended for renal impairment.
12.3 only states PK differences not identified in mild to moderate renal impairment; the provided excerpts do not explicitly state 'no dose adjustments are recommended' for renal impairment.
The risk of neutropenia and anemia remains elevated across kidney function levels with lurbinectedin.
The provided excerpts do not provide safety-by-renal-function incidence for neutropenia/anemia.
Prior bone marrow suppression increases the risk of lurbinectedin-associated myelosuppression.
No such risk relationship is stated in the provided excerpts.
Myelosuppression is the most frequent serious side effect of lurbinectedin (58% incidence).
5.1 excerpt does not provide a '58% incidence' or 'most frequent serious side effect' statement.
Active or recent chemotherapy patients require blood count monitoring before each lurbinectedin dose.
5.1 says to monitor blood counts prior to each administration generally, but the statement adds a restriction to 'active or recent chemotherapy' which is not specified in the excerpt.
Blood count monitoring is intended to avoid severe neutropenia (37% grade 3/4).
The excerpt provides monitoring instructions but does not provide a '37% grade 3/4' severe neutropenia incidence or explicitly link monitoring to that percentage.
Patients aged 75 years or older have increased severe adverse events with lurbinectedin (up to 80% incidence).
8.5 provides higher incidence of Grade 3/4 adverse reactions in ≥65 (76% vs 50%), but does not provide an 'up to 80%' figure for ≥75.
Patients with poor ECOG performance status (2-4) have increased severe adverse events with lurbinectedin (up to 80% incidence).
No ECOG-related statement or 'up to 80%' figure appears in the provided excerpts.
Pretreatment with platinum-based therapy is associated with amplified cytopenias with lurbinectedin.
No platinum pretreatment/cytopenia association is present in the provided excerpts.
QT-prolonging drugs increase the risk of arrhythmia with lurbinectedin.
No QT/arrhythmia warning or interaction is included in the provided excerpts.
Contradictions
AI Statement
Patients with bilirubin above the upper limit of normal should not receive lurbinectedin.
Label Reference
4 CONTRAINDICATIONS: 'None.' ; 2.4 Hepatic impairment: severe impairment is defined as total bilirubin > 3×ULN (avoid administration in severe hepatic impairment). No contraindication stated for bilirubin > ULN generally.
AI Statement
Patients with AST/ALT more than three times the upper limit should not receive lurbinectedin.
Label Reference
4 CONTRAINDICATIONS: 'None.' ; Provided hepatic impairment dosing modifications use bilirubin thresholds and do not state an absolute contraindication for AST/ALT >3×ULN in the excerpts.
Important Omissions
Concomitant baseline laboratory requirements for administering ZEPZELCA (ANC ≥ 1,500 cells/mm3 and platelets ≥ 100,000/mm3) and specific G-CSF guidance when ANC is low.
Importance:
Moderate
Hepatic impairment dosing details for moderate hepatic impairment (recommended dosage 1.6 mg/m2 every 21 days) and avoidance criterion for severe hepatic impairment (total bilirubin > 3×ULN).
Importance:
Moderate
No contraindications are listed in Section 4.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are contradicted or not supported by the provided label excerpts (e.g., bilirubin/AST-ALT absolute 'should not receive' statements despite 'None' contraindications in the excerpt). Unsupported quantitative incidence claims may mislead risk assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Contradictions regarding contraindications and hepatic lab thresholds; multiple unsupported safety quantifications and interactions (e.g., QT) not present in supplied excerpts.
Suggested Improvement
Remove contraindication-style statements for bilirubin > ULN and AST/ALT >3×ULN; align hepatic impairment language to the provided excerpt (severe hepatic impairment defined by total bilirubin >3×ULN with avoidance, moderate impairment by bilirubin >1.5–≤3×ULN with dose 1.6 mg/m2 every 21 days). Limit adverse reaction incidence figures and ECOG/platinum associations to what is explicitly stated in the provided label text.